跳至主要内容
临床试验/NCT02331511
NCT02331511Unknown不适用

Effect of Aspirin and Clopidogrel in Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator

Shahid Beheshti University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2015年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
100
试验地点
1
主要终点
Venus obstruction(axillary or subclavian vein) more than 50%(measure by venography)

研究概览

简要总结

The purpose of this study is to determine whether Aspirin or Clopidogrel are effective in the prevention of venous obstruction after implantation of cardiac pacemaker or defibrillator.

详细描述

There are growing numbers of endocardial permanent pacemakers (PPM) and implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT) device. Asymptomatic obstruction of the access vein reported to have a high incidence (30-50%) in some studies. This complication can cause some difficulties in follow up procedures such as device upgrading. The purpose of this study is to determine whether Aspirin or Clopidogrel are effective in the prevention of venous obstruction after implantation of cardiac pacemaker or defibrillator.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients who referred for first implantation of pacemaker, implantable cardiac defibrillator, or cardiac re synchronization therapy device

排除标准

  • history of malignancy
  • history of coagulopathy or platelet disorder
  • history of venous thromboembolism
  • history of gastrointestinal hemorrhage or active gastroduodenal ulcer in past 6 months
  • history of chronic kidney disorder or serum creatinine more than 1.5 mg/dl
  • patients who are on anticoagulant or other antithrombotic drugs or who must be on dual antiplatelet therapy.

研究组 & 干预措施

placebo

Placebo Comparator

No antiplatelet drug

干预措施: placebo (Drug)

Aspirin

Active Comparator

Aspirin 80 mg daily

干预措施: Aspirin 80 mg daily (Drug)

Clopidogrel

Active Comparator

Clopidogrel 75mg daily

干预措施: Clopidogrel 75 mg daily (Drug)

结局指标

主要结局

Venus obstruction(axillary or subclavian vein) more than 50%(measure by venography)

时间窗: 3 months

次要结局

  • major bleeding(3 months)
  • A composite of death of any cause, myocardial infarction, or cerebrovascular accident.(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mohammad Ali Akbarzadeh

Assistant proffesor of shahid beheshti university of medical sciences

Shahid Beheshti University of Medical Sciences

研究点 (1)

Loading locations...

相似试验